The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 29, 2025

Filed:

Jul. 28, 2022
Applicants:

Pfizer Inc., New York, NY (US);

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Robert Arch, St. Louis, MO (US);

Jun Zhang, Beijing, CN;

Michelle Mader, Arlington, MA (US);

Tetsuya Ishino, Boston, MA (US);

Joel Bard, Newton, MA (US);

William Finlay, Dublin, IE;

Orla Cunningham, Dublin, IE;

Ciara Reilly, Dublin, IE;

Peter Brams, Sacramento, CA (US);

Brigitte Devaux, Palo Alto, CA (US);

Haichun Huang, Fremont, CA (US);

Karla Henning, Milpitas, CA (US);

Assignees:

Pfizer Inc., New York, NY (US);

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6863 (2013.01); C07K 16/2875 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.


Find Patent Forward Citations

Loading…